Aidan: /* Management */

2022-07-24T03:20:50Z

Management

← Older revision		Revision as of 03:20, 24 July 2022
Line 3:		Line 3:
	== Background ==		== Background ==

	* Adverse reaction to [[Β-lactams\|β-lactam antibiotics]] occurring in about ~~1 to~~ 10% of ~~prolonged~~ courses		* Adverse reaction to [[Β-lactams\|β-lactam antibiotics]] occurring in about 10% of courses longer than 2 weeks
	* Higher risk with [[penicillin G]], [[nafcillin]], [[oxacillin]], [[piperacillin-tazobactam]], [[ceftriaxone]], and [[ceftaroline]]		* Higher risk with [[penicillin G]], [[nafcillin]], [[oxacillin]], [[piperacillin-tazobactam]], [[ceftriaxone]], and [[ceftaroline]]
	* Risk increases with cumulative exposure		* Risk increases with cumulative exposure
Line 11:		Line 11:

	* [[Neutropenia]]		* [[Neutropenia]]
			* Usually presents after 2 to 3 weeks of parenteral antibiotics
			* Rash in 25-50% of cases
			* May have associated [[eosinophilia]] or [[thrombocytopenia]]
	* Can progress to [[agranulocytosis]]		* Can progress to [[agranulocytosis]]

	== Management ==		== Management ==

	* ~~Stop~~ the offending ~~agent~~		* Consider stopping the offending antibiotic if ANC falls below 1
	* Other β-lactam antibiotics are probably still safe to use		* Other β-lactam antibiotics are probably still safe to use

Aidan: Created page with "{{DISPLAYTITLE:β-lactam-associated neutropenia}} == Background == * Adverse reaction to β-lactam antibiotics occurring in about 1 to 10% of prolonged courses * Higher risk with penicillin G, nafcillin, oxacillin, piperacillin-tazobactam, ceftriaxone, and ceftaroline * Risk increases with cumulative exposure * Mechanism is unclear; may be some combination of a direct toxic effect or an Hypersensitivity reaction|immune-mediated..."

2022-07-24T03:11:27Z

Created page with "{{DISPLAYTITLE:β-lactam-associated neutropenia}} == Background == * Adverse reaction to β-lactam antibiotics occurring in about 1 to 10% of prolonged courses * Higher risk with penicillin G, nafcillin, oxacillin, piperacillin-tazobactam, ceftriaxone, and ceftaroline * Risk increases with cumulative exposure * Mechanism is unclear; may be some combination of a direct toxic effect or an Hypersensitivity reaction|immune-mediated..."

New page

{{DISPLAYTITLE:β-lactam-associated neutropenia}}

== Background ==

* Adverse reaction to [[Β-lactams|β-lactam antibiotics]] occurring in about 1 to 10% of prolonged courses
* Higher risk with [[penicillin G]], [[nafcillin]], [[oxacillin]], [[piperacillin-tazobactam]], [[ceftriaxone]], and [[ceftaroline]]
* Risk increases with cumulative exposure
* Mechanism is unclear; may be some combination of a direct toxic effect or an [[Hypersensitivity reaction|immune-mediated hypersensitivity reaction]]

== Clinical Manifestations ==

* [[Neutropenia]]
* Can progress to [[agranulocytosis]]

== Management ==

* Stop the offending agent
* Other β-lactam antibiotics are probably still safe to use

== Further Reading ==

* A Review of β-Lactam-Associated Neutropenia and Implications for Cross-reactivity. ''Ann Pharmacother''. 2021;55(8):1037-1049. doi: [https://doi.org/10.1177/1060028020975646 10.1177/1060028020975646]

Β-lactam-associated neutropenia - Revision history

Aidan: /* Management */